Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.
about
No association of a set of candidate genes on haloperidol side effects.Advances in genetic studies of substance abuse in ChinaPharmacogenomics study in a Taiwan methadone maintenance cohortGenome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.Characterization of the genetic variation present in CYP3A4 in three South African populations.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemPharmacogenetics of chronic pain and its treatment.Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.Pharmacogenomics of methadone maintenance treatment.Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.Effect of amphetamine on corrected-QT interval change during methadone maintenance treatment in Taiwan: a prospective cohort study.Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.CYP gene family variants as potential protective factors in drug addiction in Han Chinese.Methadone maintenance treatment experience in Macao--prospective follow-up for initial 4.5 years.
P2860
Q30424511-E18A7342-C8E3-4F72-81EF-AD6A6A77EAA8Q33744466-3F7DA969-76E1-40AC-9FF2-35B9EDEBD53AQ34263763-2D0BC07F-4213-453E-9C5D-C5C70FC2AF38Q35968979-10E8F1E7-FB00-4FBE-9DE9-FC28A4E02F0FQ36617170-B1026A2E-CE2D-404A-9432-E3A52E509A9FQ36634077-AED67677-35F7-40FC-A1A0-9E0F5C552632Q36900075-DE79CA53-761C-4F9C-9800-D6EFF0CE11B2Q37199426-E0B5DC58-E18D-4A42-BDE7-5F84BB7AA204Q37513374-A69C5127-8A53-4642-BB16-C12B4502F5D1Q38093852-992B5984-E309-41D6-959E-2044BDC2A3D4Q38154911-5113C04D-365F-4652-B2A1-1EBEED18A980Q38184547-780092FE-C640-4835-A71D-0BECF8CA1F24Q38222510-3B2C4324-DAEC-4211-9417-91648C2D565DQ38937515-76F40A03-4FC6-4006-87B6-7C37F79ACC1EQ45935213-9889B61F-F8E3-4869-B726-0E0409355CE6Q48244859-8F1F2B25-B58C-42CD-82E6-194F10D47D74Q51306296-3692D264-112A-4A4A-962E-7CCA4B42D5A0Q52303787-79BB6A18-5759-4223-93EE-EE9E39868D27
P2860
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@en
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@nl
type
label
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@en
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@nl
prefLabel
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@en
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Genetic polymorphisms in CYP3A ...... ethadone maintenance patients.
@en
P2093
Andrew Ch Chen
Cheng-Jou Yu
Chia-Hui Chen
Chieh-Liang Huang
Ing-Kang Ho
Jia-Ni Tian
Kai-Chi Fang
Keh-Ming Lin
Lien-Wen Su
Ming-Lun Liu
P2860
P304
P356
10.2217/PGS.11.103
P577
2011-09-08T00:00:00Z